Andrew Kraft to Middle Aged
This is a "connection" page, showing publications Andrew Kraft has written about Middle Aged.
Connection Strength
0.207
-
A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma. Cancer. 2021 03 15; 127(6):894-904.
Score: 0.053
-
Angiosarcoma treated successfully with anti-PD-1 therapy - a case report. J Immunother Cancer. 2017 07 18; 5(1):58.
Score: 0.042
-
Combination therapy of recurrent prostate cancer with the proteasome inhibitor bortezomib plus hormone blockade. Cancer Biol Ther. 2011 Jul 15; 12(2):119-24.
Score: 0.027
-
Treatment of patients with metastatic melanoma with bryostatin-1--a phase II study. Melanoma Res. 1999 Dec; 9(6):599-606.
Score: 0.012
-
Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer. 1999 Jan 01; 85(1):178-87.
Score: 0.012
-
Phase I trial of weekly docetaxel, total androgen blockade, and image-guided intensity-modulated radiotherapy for localized high-risk prostate adenocarcinoma. Clin Genitourin Cancer. 2014 Apr; 12(2):80-6.
Score: 0.008
-
A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy. Anticancer Drugs. 2013 Aug; 24(7):743-53.
Score: 0.008
-
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2013 Apr; 14(4):371-82.
Score: 0.008
-
Role of thoracic radiotherapy combined with chemotherapy in limited stage small cell lung cancer (SCLC). A randomized multicenter phase III trial. Onkologie. 1990 Aug; 13(4):253-8.
Score: 0.006
-
Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009 Jul 01; 27(19):3133-40.
Score: 0.006
-
Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer. BMC Cancer. 2007 Dec 20; 7:231.
Score: 0.005
-
Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial. BMC Cancer. 2007 Dec 03; 7:221.
Score: 0.005
-
Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma. Cancer Biol Ther. 2007 Jul; 6(7):1015-7.
Score: 0.005
-
A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer. 2005 Apr 01; 103(7):1431-8.
Score: 0.004
-
Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma. Clin Cancer Res. 2000 Nov; 6(11):4205-8.
Score: 0.003
-
[Neo-adjuvant chemotherapy of head and neck cancer]. Dtsch Med Wochenschr. 1986 Jul 11; 111(28-29):1097-100.
Score: 0.001